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Summary Background TAS-106 was designed to inhibit
RNA synthesis by blocking RNA polymerases I, II, and III.
Methods This was a single-center, open-label, phase I study to
identify the maximum tolerated dose (MTD), pharmacokinet-
ics, and biologic effects of the combination of TAS-106 and
carboplatin, following a standard 3+3 design. This phase I
trial was comprised of a regimen of a 60-min IV infusion of
carboplatin on day 1 of each 21-day cycle followed by a 24-h
infusion of TAS-106, also on day 1 of each cycle. Results 39
patients were treated (21 male, 18 female, median age
62 years, range 21–80 years). Median number of prior thera-
pies was 4. Maximum Tolerated Dose (MTD) was 3 mg/m2
TAS-106 with AU 4 carboplatin. Dose-limiting toxicities were
neutropenia and thrombocytopenia, with and without growth
factor support.While no patients achieved a complete or partial
response, four patients had stable disease lasting ≥4 months,
including one patient each with ovarian, non-small cell lung,
basal cell and colorectal cancer. Conclusions In summary, the
combination of TAS-106 and carboplatin was well-tolerated,
and further studies in non-small cell lung and ovarian cancer
are warranted to assess the efficacy of this drug combination.
Keywords Phase I . Platinum . Ovarian . Non-small-cell
lung cancer . TAS-106 . Resistance
Introduction
Fluorinated pyrimidines and their derivatives such as fluo-
rouracil (5-FU) are frequently used in chemotherapy against
cancer [1]. These agents are classified as metabolic antago-
nists that target the synthesis phase (S-phase) of the cell
cycle, in which DNA synthesis occurs. Therefore, these
agents are more effective in rapidly growing tumors than
in more indolent cancers. Thus, a chemotherapeutic agent
that affecting mechanisms other than DNA synthesis would
be potentially beneficial.
In order to develop new drugs that interfere with both
DNA and RNA synthesis, the metabolism of pyrimidines
was studied, and new compounds were developed by the
molecular design method, which analyzes the biochemical
properties of the compounds [2]. The nucleoside 3’-C-
ethynylcytidine (TAS-106) was designed to inhibit RNA
synthesis [3, 4]. Unlike 5-FU, which inhibits RNA synthesis
by incorporation into the RNA strand (thereby inhibiting
processing), TAS-106 inhibits RNA synthesis by blocking
RNA polymerases I, II, and III [5, 6]. Therefore, TAS-106 is
a novel nucleoside that inhibits RNA synthesis and is antic-
ipated to exhibit a wide spectrum of antitumor activity.
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TAS-106 is phosphorylated into its active metabolite by
cytidine/uridine kinase, which is preferentially expressed by
malignant cells versus normal cells [7]. The primary active
metabolite, ethynylcytidine triphosphate (ECTP), is retained
in the body for a long time even after short-term exposure to
TAS-106 [8]. There is little or no inactivation of TAS-106 by
enzymes involving pyrimidine nucleoside and nucleotide me-
tabolism. Unchanged TAS-106 was the major drug-related
substance both in plasma and urine. Ethynyluridine was ob-
served as the minor drug-related substance. The distribution of
TAS-106 in the tumor tissue appeared to be higher and to be
retained longer than TAS-106 in serum and normal tissues,
such as the digestive tract (small and large intestine), hemato-
poietic system (spleen and bone marrow), liver, kidney, lung,
skin, testis, and brain [9]. Through pharmacological testing,
TAS-106was found to have wide and potent antitumor spectra
against human cancer xenografts [9].
Bolus and infusion regimens of TAS-106 were evaluated
in four prior trials, in order to characterize the drug’s safety
profile and identify a phase II dose [10–12]. A review of the
safety and drug exposure data from these completed trials
suggested that the best regimen for phase-II testing was
TAS-106 administered as a 24-h infusion [13–15]. This
regimen allowed greater tumor exposure to TAS-106, and
the characteristic dose-limiting toxicity (DLT) appeared to
be neutropenia instead of peripheral neurotoxicity. The
suggested phase II dose level from the TAS106-9904 study
was 6.85 mg/m2/dose [16].
Preclinical data also indicate that TAS-106 appears to
work synergistically in combination with cisplatin. One of
the challenges of combining TAS-106 and cisplatin is that
the neurotoxicity profiles of these drugs overlap. However,
unlike cisplatin, carboplatin does not commonly cause neu-
rotoxicity as a major DLT, making it a reasonable option for
combination with TAS-106. This phase I study was
conducted to determine the maximum tolerated dose
(MTD) of TAS-106 when combined with carboplatin. In
this study, we determined the safety and efficacy profiles
of this drug combination.
Methods
Eligibility criteria
Patients had to be ≥18 years old and have histologically- or
cytologically-confirmed diagnosis of a solid tumor, evidence
of disease recurrence or metastatic disease, an Eastern Coop-
erative Oncology Group (ECOG) performance status of 0–2,
and adequate hematologic, hepatic, and renal function. Patients
were excluded from the study if they had a known hypersen-
sitivity to carboplatin; radiological or clinical evidence of
brain involvement or leptomeningeal disease; clinically
evident human immunodeficiency virus (HIV), hepatitis B
virus (HBV), or hepatitis C virus (HCV) infection; ≥ grade 2
peripheral neuropathy; or serious illness or medical conditions
(e.g., congestive heart failure, previous history of myocardial
infarction within 1 year from study entry, active infection,
unstable diabetes, or psychiatric disorder that could interfere
with consent). Women who were pregnant or breast feeding
were excluded from the study. Patients were also excluded if
they received concurrent chemotherapy, investigational agents,
radiotherapy, or surgery; had previously received radiation
therapy to >30 % of bone marrow, or received any investiga-
tional drug within the prior 30 days. Patients of reproductive
capacity who refused to use appropriate pregnancy-prevention
methods during the study were also excluded. Institutional
Review Board (IRB) approval and written informed consent
from all patients were obtained before study-related procedures
were started.
Study design
This was a single-center, open-label, phase I study to identify
the MTD of the combination of TAS-106 and carboplatin.
Patient demographics are provided in Table 1. The first part
of the study was a dose-escalation following a standard 3+3






Men 21 (53.8 %)
Women 18 (46.2 %)
Primary cancer diagnosis, n (%)
Lung 14 (35.9 %)
Colon 8 (20.5 %)
Breast 3 (7.7 %)
Ovary 2 (5.1 %)
Rectal 2 (5.1 %)
Head & neck, SCC 1 (2.6 %)
Head & neck, adenoid cystic carcinoma 1 (2.6 %)
Pancreas 1 (2.6 %)
Other 7 (17.9 %)
Prior carboplatin, n (%) 10 (29 %)
ECOG performance status score, n (%)
0 6 (15.4 %)
1 29 (74.4 %)
2 3 (7.7 %)
N.D. 1 (2.6 %)
ECOG Eastern Cooperative Oncology Group; N.D. not determined;
SCC squamous cell carcinoma
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design in order to determine theMTD and recommended phase
II dose. The starting dose of TAS-106 was 2.0 mg/m2, and the
starting target area under the concentration-versus-time curve
(AUC) of carboplatin was initially limited to 4 mg/ml/min
because of the potential for bone marrow toxicity when
TAS-106 was combined with carboplatin. The TAS-106 was
administered intravenously as a 24-h infusion on Day 1 of
each 3-week cycle. Carboplatin was administered as a 60-min
intravenous infusion prior to TAS-106 on Day 1 of each cycle.
In the dose-escalation phase, patients were enrolled in
cohorts of three patients until a dose-limiting toxicity (DLT)
was observed. If one patient experienced a DLT, a total of
six patients were enrolled at that dose level. Dose escalation
continued until more than one of six patients in a cohort
experienced a DLT. Once an MTD was identified, at least
nine patients were to be enrolled at that dose level.
DLTs and the MTD
DLTs were study drug-related events defined as any of the
following occurring during treatment Cycle 1: any grade 3 or
higher non-hematological toxicity (excluding nausea and
vomiting); any grade 3 or higher nausea or vomiting
uncontrolled by aggressive antiemetic support; grade 4
granulocytopenia lasting >7 days despite the administration
of granulocyte-macrophage colony-stimulating factor (GM-
CSF) or granulocyte colony-stimulating factor (G-CSF); fever
(≥38.5 °C) with grade 3 or higher granulocytopenia of any
duration; grade 4 thrombocytopenia; inability to begin the
next cycle of treatment within 2 weeks of scheduled dosing
due to unresolved toxicity, grade 2 non-hematological toxicity
which required dose reduction; or any grade 3 or higher
neurological toxicity. The MTD was defined as the highest
dose level at which one or fewer patients experienced a DLT.
Dose reductions were allowed for toxicity.
Safety evaluation
Adverse events were recorded for all patients who received at
least one dose of study drug (Table 2). Severity was assessed
according to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (NCI CTCAE), version 3.0.
Vital signs were measured at various time points up to 4 h after
infusion and regularly between infusions. Electrocardiograms
were obtained prior to infusion and 30 min and 3 h after
infusion during Cycle 1. Hematology, blood chemistry, and
urine values were monitored regularly, and physical and neu-
rologic examinations were regularly performed.
Pharmacokinetics (PK)
PK studies were conducted on plasma samples collected on
Day 1 of Cycle 1 after carboplatin infusions (pre-dose of
TAS-106) and again 10 min prior to the end of TAS-106
infusion. To determine the plasma TAS-106 concentration,
samples were subjected to ion-exchange solid-phase extrac-
tion and TAS-106 concentration was determined using liq-
uid chromatography/tandem mass spectrometry (LC-
MS/MS). The lower limit of quantitation for plasma TAS-
106 was 1 ng/mL. To determine plasma carboplatin concen-
tration, 2 % Triton-X solution and internal standard solution
were added to plasma samples and mixed. The solution was
injected into an inductively coupled plasma-mass spectrom-
eter for approximately 30 s at a pump speed of 0.5 revolu-
tions per second. The lower limit of quantitation for plasma
carboplatin was 1 ng/mL. TAS-106 and carboplatin PK
analyses were conducted at the same time.
Efficacy evaluation
Treatment efficacy was evaluated by CT or MRI per Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) 1.0
[17] in all organs in which disease was present, including
the brain, before treatment and every two cycles thereafter.
Briefly, complete response (CR) was the disappearance of
all lesions; partial response (PR) was a ≥30 % reduction in
the sum of the longest diameters of the lesions; stable
disease (SD) was sum of longest diameters not decreased
more than 30 % and not increased more than 20 %; and
progressive disease (PD) was a ≥20 % increase in the sum of
the longest diameters of the lesions.
Statistical analysis
Descriptive statistics are provided for demographic, safety,
PK, and efficacy data. Categorical data are summarized by
frequency and percentages; continuous data are summarized
by mean and standard deviation (SD) or median and range,
as appropriate. All data were processed and summarized




Thirty-nine patients were enrolled at the University of Texas
MD Anderson Cancer Center, Houston, TX beginning
in June 2008. All patients were included in the safety and
efficacy analyses. Patient demographics are summarized in
Table 1. Patients received a median of two treatment cycles
(range 1–12). Patients discontinued treatment due to disease
progression (n=30), neuropathy which did not improve to
grade 1 within 2 weeks (n=1), patient withdrawal (n=1),
death (n=1), and other reasons (n=6).
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Dose escalation
Patients were enrolled in the following dose cohorts:
2.0 mg/m2 IV TAS-106 and an AUC of 4 mg/ml/min IV
carboplatin; 3.0 mg/m2 TAS-106 and an AUC of 4
carboplatin; and 3.0 mg/m2 TAS-106 and an AUC of 5
carboplatin. Patients received TAS-106 and carboplatin
once every 3 weeks.
DLTs and MTD
The first five patients treated at dose level 1 experienced no
DLTs. Two of the first three patients treated at dose level 1
received G-CSF, which was not allowed per protocol. Two
additional patients were added to the dose level to ensure
three patients were included who did not receive G-CSF. Six
patients were then treated at dose level 2, and one patient
experienced a DLT (inability to begin treatment within
2 weeks of the scheduled dose due to unresolved neutrope-
nia). In dose level 3, two out of five patients experienced a
DLT (one patient had a fever >38.5 °C with > grade 3
granulocytopenia, and the other patient had grade 4
granulocytopenia lasting >5 days without GM-CSF or
G-CSF). Thus, dose level 3 was determined to be above
the MTD.
To investigate whether or not supportive treatment
with G-CSF or GM-CSF would allow higher dose levels
to be tolerable, the protocol was amended to allow G-
CSF or GM-CSF as primary supportive care. Three ad-
ditional patients were added at dose level 2. None of
these patients experienced a DLT, and six additional
patients were added at dose level 3. Two of these six
patients experienced a DLT (both experienced grade 4
thrombocytopenia). Therefore, dose level 2 was consid-
ered the MTD and recommended phase II dose. A total
of 23 patients were enrolled at dose level 2, and of these,
one patient experienced a DLT.
Safety
All 39 patients received at least one dose of study drug
and were evaluated for safety and tolerability; all patients
Table 2 Adverse events possi-
bly related to study drugs
aDose of TAS-106 (mg/m2, IV
every 3 weeks) and carboplatin
(AUC, IV, every 3 weeks)
Dose levela 2.0+4 (n=5) 3.0+4 (n=23) 3.0+5 (n=11) Total (N=39)
NCI-CTCAE grade 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4
Hematologic
Anemia 1 1 5 1 3 3 8
Febrile neutropenia 1 1
Leukocytosis 1 1 1 1
Leukopenia 2 6 3 2 9
Lymphopenia 1 1
Neutropenia 3 2 2 16 1 9 6 27
Pancytopenia 1 1
Thrombocytopenia 4 2 3 3 7 5
Non-hematologic
Fatigue 1 1 1 1
Decreased hemoglobin 1 2 3 6
Peripheral neuropathy 1 1 1 2 1
Hypoaesthesia 2 2
Decreased vibratory sense 1 1
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experienced at least one adverse event. One patient
required a dose reduction of carboplatin. One patient
discontinued study treatment due to neuropathy > grade
2 which did not improve to grade 1 within 2 weeks.
Neutropenia was the most frequently observed toxicity
(Table 2).
A total of three patients died within 30 days of study
treatment discontinuation. Two patients died of cancer-
related causes 23 and 29 days following treatment discon-
tinuation. The third patient died of pneumonia, which was
unrelated to the study treatment.
Neurological assessment
Patients had neurological monitoring throughout the study
treatment due to the potential neurotoxic effect of TAS-106.
Numbness occurred in nine patients (23.1 %), followed by
paresthesia and vibration sensation in six patients (15.3 %)
each. Abnormalities in walking/gait, light touch responsive-
ness, deep-tendon reflexes, and 2-point discrimination oc-
curred in three patients (7.7 %) each.
Pharmacokinetics
The maximum plasma concentrations (Cmax) of carboplatin
and TAS-106 were determined to analyze their pharmaco-
kinetic behavior when carboplatin and TAS-106 were
administered sequentially over a 60-min period and the
subsequent 24-h period, respectively, both by intravenous
infusion.
The (Cmax) of TAS-106 and carboplatin were determined
by dose levels. The plasma Cmax of carboplatin were 18214±
2625.1 ng/mL, 24553±6861.6 ng/mL, and 23357±
6236.8 ng/mL, at respective dose levels 1, 2, and 3. The
plasma TAS-106 Cmax 10 min before the end of TAS-106
infusion were 17.6±2.9 ng/mL, 27.9±9.1 ng/mL, and 29.6±
10.7 ng/mL, at respective dose levels 1, 2, and 3. The mean
plasma concentration of TAS-106 at 10 min before the end of
infusion was generally proportional to TAS-106 dose.
Efficacy
All 39 patients who received study treatment were included in
efficacy evaluation. Five patients did not have final data
available; three of the five patients did not receive more than
one cycle of treatment, and two of the five patients did not
have target lesions assessed at baseline and were therefore not
available for RECIST evaluation. No patients achieved a CR
or PR. Fifteen patients achieved SD (38.5 % of all patients
who received study treatment), including one patient at dose
level 1 (20.0 % of patients treated at dose level 1), 10 patients
at dose level 2 (52.6 % of patients treated at dose level 2), and
four patients at dose level 3 (40.0 % of patients treated at dose
level 3). Patients who achieved SD had a diagnosis of lung
cancer (n=6 of 11 patients with lung cancer), colorectal cancer
(n=3 of 9 patients with colorectal cancer), and ovarian cancer
(n=2 of 2 patients with ovarian cancer). Four patients had
stable disease lasting ≥4 months (one patient each with ovar-
ian, non-small cell lung, basal cell, and colorectal cancer).
Discussion
We treated 39 patients with TAS-106 and carboplatin at the
MD Anderson Cancer Center in an open-label, phase I study
investigating the safety and tolerability of concomitant
administration of these anti-cancer drugs. In prior phase I
studies that tested TAS-106 alone in a 24-h infusion, the
MTD, and thus the recommended dose for subsequent phase
II studies, was 6.85 mg/m2 [16]. However, given the poten-
tially synergistic toxicity of using TAS-106 and carboplatin
together, we opted to initially enroll patients in the following
dose cohorts: 1) 2.0 mg/m2 IV TAS-106 and an AUC of
4 mg/ml/min IV carboplatin; 3.0 mg/m2 TAS-106 and an
AUC of 4 carboplatin; and 3.0 mg/m2 TAS-106 and an AUC
of 5 carboplatin. We found the MTD to be 3.0 mg/m2 TAS-
106 and carboplatin AUC of 4.
A total of five patients experienced DLTs. No DLTs
occurred at dose level 1. One DLT occurred at dose level
2, of the 23 total treated, and four DLTs ultimately occurred
at dose level 3, of the 11 total patients treated. In the first
treatment round at dose level 3, two of five patients experi-
enced DLTs (granulocytopenia). In the next group of pa-
tients treated with dose level 3, we amended our protocol to
include concurrent supportive treatment with either G-CSF
or GM-CSF, in an effort to increase study drug tolerability.
Nonetheless, two of six patients in this group experienced a
hematologic DLT (thrombocytopenia), which was not negated
by supplemental G-CSF or GM-CSF administration. There-
fore, we determined dose level 3 to be above the MTD.
All patients experienced at least one adverse event. The
observed adverse events reflected minimal neurotoxic ef-
fects of our study drug combination; however, hematotoxicity
was observed. The most common adverse event was neutro-
penia (n=33). Three patients died within 1 month of study
treatment discontinuation, from causes unrelated to the study
treatments.
Similar to our current study, previous studies with TAS-
106 have found neurotoxicity [16]. In patients receiving IV
bolus TAS-106, 45.8 % of patients (11 out of 24) experi-
enced neurotoxicity [16]. The majority of patients experi-
enced only grade 1 neurotoxicity [16]. Four patients
experienced grade 2 toxicity, and one patient experienced
grade 3 neurotoxicity (grade 3 peripheral neuropathy) [16].
In patients receiving IV bolus TAS-106, two patients
discontinued treatment due to grade 3 peripheral neuropathy
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(n=1) and grade 2 tremors (n=1) [16]. Neurological toxicity
was observed in 13 patients (33.3 %). Five patients experi-
enced peripheral neuropathy, four patients experienced
headache, two patients experienced hypoaesthesia, and two
patients experienced tremor [16]. In our present study,
numbness occurred in nine patients (23.1 %), followed by
paresthesia and vibration sensation in six patients (15.3 %)
each. Abnormalities in walking/gait, light touch responsive-
ness, deep-tendon reflexes, and 2-point discrimination oc-
curred in three patients (7.7 %) each.
We evaluated PK of TAS-106 and carboplatin by evalu-
ating plasma Cmax levels of these drugs at the administered
dose levels. Post-infusion carboplatin Cmax levels were
18214±2625.1 ng/mL, 24553±6861.6 ng/mL, and 23357±
6236.8 ng/mL, at respective dose levels 1, 2, and 3. End-
infusion TAS-106 Cmax levels were 17.6±2.9 ng/mL, 27.9±
9.1 ng/mL, and 29.6±10.7 ng/mL, at respective dose levels
1, 2, and 3. The mean plasma concentration of TAS-106 at
10 min before the end of infusion was generally proportion-
al to the TAS-106 dose. The antitumor effect of TAS-106 is
seen at the dose of 0. 3 mg/kg to 1 mg/kg in animal models.
When TAS-106 was administered to rats via single IV, the
AUC was 1512.9 ngxhr/mL. Based on the PK results in this
clinical study with 24-h continuous IV infusion (CIV), the
AUC in humans is roughly estimated about 670 ngxhr/mL.
However, due to the differences between clinical and animal
models plus treatment schedule, it is difficult to simply compare
these results. AUC in this clinical study is relatively equal to or
lower than AUC in animal models.
The dose of carboplatin of recommended phase II dose is
AUC 4, which is suboptimal for most platinum doublets used
in NSCLC and ovarian cancer except in the elderly. Due to
toxicity, we were not able to escalate the dose. However,
despite the suboptimal dose of carboplatin, we observed stable
disease in patients with NSCLC and ovarian cancer due to
possible synergism between carboplatin and TAS-106.
In summary, the combination of TAS-106 and
carboplatin was well-tolerated at the determined MTD and
recommended phase II dose (3.0 mg/m2 IV TAS-106 and an
AUC of 4 IV carboplatin, every 3 weeks). While no patients
achieved a CR or PR, four patients had stable disease lasting
≥4 months, including one patient each with ovarian, non-
small cell lung, basal cell, and colorectal cancer. Having
determined the safety profile of dual TAS-106 and
carboplatin administration in this phase I study, further
studies in non-small cell lung and ovarian cancer to assess
this drug combination’s efficacy are warranted.
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